HRJR7T.jpg

Harnessing The Power of
NK Cells to Defeat Cancer

 

News & Events

 

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

News & Events

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer

June 3rd, 2020

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2
(COVID-19)

April 7th, 2020

Cytovia CEO Dr. Daniel Teper Featured on MSQ Webinar Series

March 24th, 2020

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

“Precision CAR-NK Cells produced from induced pluripotent stem cells have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy and broad patient access. We expect to bring the first iPSC CAR-NKs to initial clinical trials starting in 2021.”

- Daniel Teper, Cytovia Therapeutics CEO

 

Media & Press Updates

Cytovia Therapeutics Wins Top Industry Award

March 1, 2025

Offsite Takeaways: Doing it the Cytovia Therapeutics Way

March 1, 2025

New Startup Changing The Game

March 1, 2025